Day: January 7, 2021

 Revenus records prévus pour le 4èmetrimestre et l’exercice financier 2020Lettres « Study May Proceed » de la FDA reçues pour l’essai de la phase 3 de la tésamoréline dans le NASH et de la phase 1 du TH1902 dans différents cancersMONTRÉAL, 07 janv. 2021 (GLOBE NEWSWIRE) — Theratechnologies Inc. (Theratechnologies ou la Société) (TSX: TH) (NASDAQ: THTX), une société biopharmaceutique commerciale axée sur le développement et la commercialisation de traitements innovateurs, a annoncé aujourd’hui les estimations des revenus nets pour son quatrième trimestre et son exercice financier complet clos le 30 novembre 2020 et fournit des mises à jour sur ses activités de recherche et de développement.Les revenus nets consolidés de la Société pour le quatrième trimestre de l’exercice financier 2020 sont estimés entre 18,9 millions USD et 19,2...

Raison sociale de l’émetteur : Crédit Agricole S.A. – SA au capital de 8 750 065 920 eurosImmatriculée sous le n° 784 608 416 R.C.S. NANTERRESiège social : MONTROUGE (92120) 12, place des États-Unis* Nombre de droits de vote exerçables : Nombre de droits de vote théoriques – Actions privées de droits de vote (auto détention …)Pièce jointeDECLARATION DES DROITS DE VOTE DE DECEMBRE 2020

COLUMBUS, Ohio, Jan. 07, 2021 (GLOBE NEWSWIRE) — L Brands, Inc. (NYSE: LB) reported net sales of $3.836 billion for the nine weeks ended Jan. 2, 2021, compared to net sales of $3.906 billion for the nine weeks ended Jan. 4, 2020. Comparable sales increased 5 percent for the nine weeks ended Jan. 2, 2021, compared to the nine weeks ended Jan. 4, 2020.At Bath & Body Works, comparable sales increased 17 percent for the nine weeks ended Jan. 2, 2021, including a comparable sales increase of 5 percent in stores and 64 percent sales growth in the direct channel. The merchandise margin rate for the quarter-to-date period increased significantly.At Victoria’s Secret, comparable sales decreased 9 percent for the nine weeks ended Jan. 2, 2021, including a comparable sales decrease of 23 percent in stores and 24 percent sales growth in...

Borgarráð samþykkti á fundi sínum 7. janúar 2021 útgáfuáætlun Reykjavíkurborgar fyrir fyrri hluta árs 2021.Skuldabréfaútboð Reykjavíkurborgar verða á eftirfarandi dögum: 27. janúar, 3. mars, 14. apríl, 5. maí og 2. júní.Gert er ráð fyrir að lántakan verði framkvæmd með stækkun á virkum skuldabréfaflokkum borgarsjóðs, þ.e. í skuldabréfaflokkum RVK 32 1, RVKG 48 1 (verðtryggðir) og í skuldabréfalokkum RVKN 35 1 og RVKNG 40 1 (óverðtryggðir).Samkvæmt samþykktri fjárhagsáætlun fyrir árið 2021 er gert ráð fyrir að borgarsjóður taki lán vegna framkvæmda og reksturs á árinu 2021 fyrir allt að 34.400 mkr.Tilkynnt verður um fyrirkomulag einstakra útboða í fréttakerfi NASDAQ OMX á Íslandi a.m.k 1 virkum degi fyrir útboð.Reykjavíkurborg áskilur sér allan rétt til að víkja frá áætlun þessari og mun þá tilkynna um breytingar þar að lútandi í fréttakerfi...

Top-line results expected H1 2022Sepofarsen is a potential first-in-class RNA therapy for the treatment of LCA10, a rare inherited retinal disorder that leads to blindnessLEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) —  ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced it has completed patient enrollment in its Phase 2/3 Illuminate study of sepofarsen for the treatment of Leber Congenital Amaurosis 10 (LCA10) due to the p.Cys998X mutation in the CEP290 gene. With enrollment completed, top-line results are expected in the first half (H1) of 2022.Illuminate is a Phase 2/3 trial, which randomized 36 patients aged eight years or older to receive either sepofarsen...